In 2011, M. Elashoff, from the Larry L. Hillblom Islet Research Center at David Geffen School of Medicine and Department of Biomathematics at University of California, Los Angeles, published a study titled “Pancreatitis, Pancreatic, and Thyroid Cancer with Glucagon like Peptide-1-based Therapies”, wherein concerns regarding risk for pancreatitis and pancreatic and thyroid cancers

Studies have shown that pancreatitis is associated with the use of exenatide (Byetta, Bydureon), liraglutide (Victoza), and sitagliptin (Januvia, Janumet, Janumet XR, Juvisync) and other glucagon like peptide 1 (GLP-1) receptor agonists.  The pancreatitis associated with these therapies and medications may increase the risks for pancreatic cancer.  Experiments done on mice and rats

Author S. Raimondi from the European Institute of Oncology in Milan, Italy, wrote an article titled “Pancreatic Cancer in Chronic Pancreatitis; Aetiology, Incidence, and Early Detection”.  Chronic pancreatitis, acute pancreatitis, and pancreatic cancer are primarily responsible for most of the negative effects of exocrine pancreatic disease.  The pancreas is a flat gland found

Some studies and anecdotal reports have shown that pancreatitis may cause an individual to develop, or be at a higher risk to develop pancreatic cancer.  Pancreatitis is defined as inflammation in the pancreas.  The pancreas produces enzymes that help with digestion as well as produce hormones that regulate the way your body processes sugar.  Pancreatitis

Just got this in my email from the FDA:

Byetta (exenatide) – Renal Failure

Audience: Endocrine and nephrology healthcare professionals

FDA notified healthcare professionals of revisions to the prescribing information for Byetta (exenatide) to include information on post-marketing reports of altered kidney function, including acute renal failure and insufficiency. Byetta, an incretin-mimetic, is approved